Consensus price target for Jiangsu Nhwa Pharmaceutical Co. decreased by 10.24% to CN¥27.71MSN·Oct 4, 2026 at 11:31 AM002262+2.35%
NHWA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.106 billion yuan, a year-on-year increase of 8.42%Zhitong·Oct 24, 2025 at 08:27 AM002262+2.35%
NHWA: The hydrochloride of Tizanidine tablets has obtained a drug registration certificateZhitong·Sep 19, 2025 at 07:54 AM002262+2.35%
Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit upZhitong·Sep 15, 2025 at 01:43 AM603127-6.22%06127-7.70%
NHWA released its performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38%Zhitong·Jul 29, 2025 at 09:25 AM002262+2.35%
NHWA's chairman Sun Pengsheng increased his holdings by 237,900 sharesZhitong·Jun 17, 2025 at 08:33 AM002262+2.35%
NHWA and EASTON BIOPHARMACEUTICALS have reached a strategic cooperationZhitong·Jun 5, 2025 at 06:19 AM688513-4.24%002262+2.35%
NHWA: The innovative drug NH600001 emulsion injection is expected to file for NDA this yearZhitong·May 15, 2025 at 03:51 AM002262+2.35%
NHWA released its first-quarter performance, with a net profit attributable to the parent company of 301 million yuan, a year-on-year increase of 13.35%Zhitong·Apr 18, 2025 at 07:48 AM002262+2.35%
NHWA: NH280105 has initiated Phase I clinical trials in Australia and completed the enrollment and administration of the first subjectZhitong·Apr 14, 2025 at 08:01 AM002262+2.35%
NHWA: Has already applied AI in drug research and developmentZhitong·Apr 10, 2025 at 05:46 AM002262+2.35%
NHWA released its 2024 annual performance, with a net profit attributable to the parent company of 1.144 billion yuan, an increase of 10.28%Zhitong·Mar 28, 2025 at 10:41 AM002262+2.35%
